Karp JE - Search Results

1

Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk features.

Karp JE, Smith BD, Gojo I, Lancet JE, Greer J, Klein M, Morris L, Levis MJ, Gore SD, Wright JJ, Garrett-Mayer E. Karp JE, et al. Clin Cancer Res. 2008 May 15;14(10):3077-82. doi: 10.1158/1078-0432.CCR-07-4743. Clin Cancer Res. 2008. PMID: 18483374 Free PMC article. Clinical Trial.

2

Prognostic importance of immunophenotyping in adults with acute myelocytic leukaemia: the significance of the stem-cell glycoprotein CD34 (My10).

Geller RB, Zahurak M, Hurwitz CA, Burke PJ, Karp JE, Piantadosi S, Civin CI. Geller RB, et al. Among authors: karp je. Br J Haematol. 1990 Nov;76(3):340-7. doi: 10.1111/j.1365-2141.1990.tb06365.x. Br J Haematol. 1990. PMID: 1702006

3

Cure of acute myelocytic leukemia in adults: a reality.

Geller RB, Saral R, Karp JE, Santos GW, Burke PJ. Geller RB, et al. Among authors: karp je. Leukemia. 1990 May;4(5):313-5. Leukemia. 1990. PMID: 2201825 Review.

4

Phase I and pharmacodynamic study of taxol in refractory acute leukemias.

Rowinsky EK, Burke PJ, Karp JE, Tucker RW, Ettinger DS, Donehower RC. Rowinsky EK, et al. Among authors: karp je. Cancer Res. 1989 Aug 15;49(16):4640-7. Cancer Res. 1989. PMID: 2568175

5

Cures of leukemia with aggressive postremission treatment: an update of timed sequential therapy (Ac-D-Ac).

Burke PJ, Karp JE, Geller RB, Vaughan WP. Burke PJ, et al. Among authors: karp je. Leukemia. 1989 Oct;3(10):692-4. Leukemia. 1989. PMID: 2674562

6

Secondary acute myelocytic leukemia after adjuvant therapy for early-stage breast carcinoma. A new complication of cyclophosphamide, methotrexate, and 5-fluorouracil therapy.

Geller RB, Boone LB, Karp JE, Davidson N, Selonick SE, Edwards J, Burke PJ. Geller RB, et al. Among authors: karp je. Cancer. 1989 Aug 1;64(3):629-34. doi: 10.1002/1097-0142(19890801)64:3<629::aid-cncr2820640311>3.0.co;2-l. Cancer. 1989. PMID: 2743258

7

In vivo cell growth and pharmacologic determinants of clinical response in acute myelogenous leukemia.

Karp JE, Donehower RC, Enterline JP, Dole GB, Fox MG, Burke PJ. Karp JE, et al. Blood. 1989 Jan;73(1):24-30. Blood. 1989. PMID: 2910362 Free article.

8

An approach to intensive antileukemia therapy in patients with previous invasive aspergillosis.

Karp JE, Burch PA, Merz WG. Karp JE, et al. Am J Med. 1988 Aug;85(2):203-6. doi: 10.1016/s0002-9343(88)80343-7. Am J Med. 1988. PMID: 3165248

9

Remission of rheumatoid arthritis with the successful treatment of acute myelogenous leukemia with cytosine arabinoside, daunorubicin, and m-AMSA.

Roubenoff R, Jones RJ, Karp JE, Stevens MB. Roubenoff R, et al. Among authors: karp je. Arthritis Rheum. 1987 Oct;30(10):1187-90. doi: 10.1002/art.1780301017. Arthritis Rheum. 1987. PMID: 3479115

10

Favorable outcome of invasive aspergillosis in patients with acute leukemia.

Burch PA, Karp JE, Merz WG, Kuhlman JE, Fishman EK. Burch PA, et al. Among authors: karp je. J Clin Oncol. 1987 Dec;5(12):1985-93. doi: 10.1200/JCO.1987.5.12.1985. J Clin Oncol. 1987. PMID: 3681380

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

290 results

Search Page

Filters